Fig. 1.

Long-term niraparib treatments. a A schematic outline of the long-term treatment experiments. Single-cell clones were expanded over a period of 20 days (DT40 cell lines) or 30 days (DLD-1 and SUM149PT cell lines). A sample was taken for sequencing as soon as a sufficient number of cells was available (“starting clone”). Further single-cell cloning was performed at the end of the treatment; one clone was sequenced from each treated cell population. b Doubling time of the indicated cell lines during continuous mock or niraparib treatment. The p values of significant changes are shown (t test). b A comparison of the niraparib sensitivity of WT and BRCA1^–/– DT40 cell lines using cytotoxicity assays. c–e Measurement of the niraparib sensitivity of the experimental cell lines using cytotoxicity assays. The mean and SEM of three independent experiments is shown in b–e. NS not significant